December 2014

New Product - Incruse Ellipta

Incruse Ellipta (umeclidinium (as bromide)) is a long-acting muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic acetylcholine receptors on airway smooth muscle. Incruse Ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Incruse Ellipta is contraindicated in patients with severe milk protein allergy. Incruse Ellipta (62.5 mcg) is available as a moulded plastic inhaler containing an aluminium foil laminate strip of 30 regularly distributed blisters.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au